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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, ElsevierBackground/purpose: Although Down syndrome (DS) patients have a higher risk of developing
transient myeloproliferative disorder (TMD) and acute leukemia, very little data is available on
long-term outcome in Taiwanese patients. The current study was designed to determine the
clinical characteristics and treatment outcome of DS patients with TMD or acute leukemia
(AL).
Methods: In 25 consecutive DS patients with TMD or AL enrolled from 1990 to 2012, clinical
manifestations and treatment protocols were investigated and GATA1 (GATA binding protein
1) mutations were identified. Among 16 DS-acute myeloid leukemia (DS-AML) patients, clinical
outcomes were compared between survivors and nonsurvivors.
Results: Most of our DS patients had TMD (32%), acute megakaryoblastic leukemia (24%), or
acute erythromegakaryoblastic leukemia (16%). The median follow-up time was 22.5 months
(1e230 months). The age was younger and the hemoglobin (Hb) level and platelet count were
higher in TMD patients than in leukemia patients. Among DS-AML patients, the Hb level was
higher in survivors than nonsurvivors (8.8  2.7 g/dL vs. 5.8  2.4 g/dL; p Z 0.044) and the
age was older in relapsed patients than in nonrelapsed patients (43.8  18 months old vs.
21.6  8.6 months old; pZ 0.025). The 3-year overall survival (OS) rate was 44%, higher in pa-
tients receiving appropriate chemotherapy than in those receiving inadequate treatmenthave no conflicts of interest relevant to this article.
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Outcome of Down syndrome with leukemia 95(63.6% vs. 0%, pZ 0.001), and higher in those diagnosed with TMD or AL after 2008 than before
2008 (33.3% vs. 75%; p Z 0.119).
Conclusion: Outcome in DS-AML patients is optimal if appropriate treatment is provided. With
modification of the treatment strategy in 2008, OS increased in Taiwan.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Trisomy 21 [Down syndrome (DS); MIM #190685; a common
chromosome aneuploidy] is associated with an increased
risk of early-onset hematopoietic disorders.1 Around 10% of
newborns with DS develop transient myeloproliferative
disorder (TMD).2 DS children have a 50-fold increased inci-
dence of acute leukemia during the first 5 years of life.3,4
The acute leukemias in approximately 60% of affected DS
children are myeloid, with at least 50% of these being acute
megakaryoblastic leukemia (AMKL).5 Mutations in exon 2 of
the GATA1 (GATA binding protein 1) gene, resulting in a
premature stop codon within the N-terminal activation
domain (i.e., GATA1s, a truncated form of GATA1) have
been detected in almost all TMD and DS AMKL cases.6e9
Both GATA1s and GATA1 have similar DNA binding abilities
and interact with partner proteins, such as ‘‘Friend of
GATA1’’ (FOG1).10 Expression of this mutated form poten-
tially contributes to the uncontrolled proliferation of poorly
differentiated megakaryocytic precursors.11
Acute myeloid leukemia (AML) in patients with DS is
referred to as myeloid leukemia associated with DS (DS-
AML) in the 4th edition of the World Health Organization
classification.4 The overall survival (OS) of DS-AML patients
is approximately 80%.12e19 However, more accurate pre-
natal screening in Taiwan in recent years has led to fewer
DS births, and fewer DS-TMD or DS-acute leukemia (DS-AL)
cases are available for study. In general, the treatment
protocols for DS-AL patients are based on the recommen-
dations of the Taiwan Pediatric Oncology Group (TPOG).
Because reports of clinical presentations or long-term
outcome in the early period are sporadic and few in
number,20e23 the present study aimed to investigate the
long-term outcome in Taiwanese patients with DS-TMD or
DS-AL and to determine the risk factors for DS-TMD or DS-
AL.
Methods
Patients and sample collection
We retrospectively reviewed the medical records of 25
consecutive DS patients with hematopoietic disorders
diagnosed in our hospital (or whose samples were sent to
our hospital for GATA1 mutation analysis) from 1990 to
2012. DS was diagnosed shortly after birth using karyotype
analysis and clinical manifestations. TMD was diagnosed
before the age of 3 months by the presence of peripheral
blood nonerythroid blasts and by reduction in the periph-
eral blood blast cell percentage occurring in response tocytoreductive therapy or spontaneously.24 Acute leukemia
was diagnosed by morphologic, biochemical, immunophe-
notypic, and cytogenetic analysis of bone marrow or pe-
ripheral blood and classified according to
FrencheAmericaneBritish (FAB) criteria.25 Age at onset,
sex, initial white blood cell count, blast percentage, he-
moglobin (Hb) level, platelet count, levels of alanine
transaminase, aspartate transaminase, lactate dehydroge-
nase, and uric acid, karyotype results, immunophenotyping
results, treatment regimens, and outcomes were all retro-
spectively obtained from the charts. Study protocol
approval was obtained from our institutional ethics com-
mittee (No. 201312034RINC).
Chemotherapy
The treatment protocols for DS with AL are based on the
recommendations of the TPOG and include the standard
protocol for acute lymphoblastic leukemia,26 and several
modifications of the standard protocol for de novo AML
(i.e., the TPOG AML 901 protocol, AML 97A protocol, and
AML 97B protocol before and during 2008 and the TPOG
AML-DS 2008 protocol after 2008).27 The protocol-specified
treatment periods were approximately 1 year.
The TPOG AML 901 protocol used since 1990 consisted of
three steps: induction [i.e., treatment with epirubicin,
cytosine arabinoside (Ara-C), and 6-thioguanine (6-TG)];
consolidation (i.e., treatment with etoposide and cyclo-
phosphamide), and maintenance [i.e., treatment with
epirubicin, Ara-C, 6-TG, etoposide, cyclophosphamide,
mercaptopurine, and methotrexate (MTX)]. The AML 901
protocol was revised in 1997 and the resulting AML 97A and
AML 97B protocols differed from their predecessor as fol-
lows. The AML 97B protocol consisted of the same three
steps but used idarubicin instead of epirubicin and added
mitoxantrone. The AML 97A protocol consisted of only two
steps: induction with Ara-C and idarubicin, and post-
remission with high-dose Ara-C (1 g/m2), etoposide,
mitoxantrone, and idarubicin. The DS 2008 protocol used
the half dose regimen of the AML 97A protocol but reduced
the Ara-C dose by 25%, added intrathecal MTX to the in-
duction regimen, and used L-asparaginase instead of
mitoxantrone in the AML 97A consolidation regimen. In our
study, use of either the full- or half-dose AML 901, AML 97A,
or AML 97B protocols and the AML DS 2008 protocol in DS-
AML patients was regarded as standard treatment. The
use of palliative or partial treatment was regarded as
incomplete treatment. Our patients were followed up from
January 1990 to June 2014 inclusively. The duration of OS
was measured from the time of diagnosis to the date of
death or last follow up.
Figure 1 Percentage of patients with each disease. Most
patients had transient myeloproliferative disorder (TMD; 32%),
acute megakaryoblastic leukemia (AML, M7; 24%), or acute
erythromegakaryoblastic leukemia (AML, M6/M7; 16%).
Table 1 Comparison of clinical characteristics between
TMD and DS-AL patients.
TMD DS-AL p
Sex (M/F) 3/5 10/7 0.286
Age (mo) 0.34  0.46 29.1  15.7 < 0.001
WBC count (103/mL) 104  146 28  48 0.061
Hb (g/dL) 12.7  4.4 6.9  2.7 < 0.001
Platelet count 165  223 35.9  35.1 0.026
96 M.-J. Li et al.GATA1 mutation analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes or bone marrow aspirates using a QIAamp DNA Blood
Mini Kit (Qiagen, Valencia, CA, USA). GATA1 exon 2 coding
regions and their flanking intronic sequences were ampli-
fied using polymerase chain reaction (PCR) (primer se-
quences and protocol available in Table S1). For those
samples found to be negative for exon 2 mutation, the
whole GATA1 gene was sequenced. The PCR products were
purified using the Gel-M Gel Extraction System (Viogene,
Taipei, Taiwan) and analyzed by direct sequencing using
the ABI Prism Big Dye dideoxy chain terminator cycle
sequencing kit and the ABI Prism 310 genetic analyzer
(Applied Biosystems, Bedford, MA, USA). The nucleotides of
the GATA1 complementary DNA were numbered starting
from the translation initiation site (NM_000023.10). Sam-
ples of 13 DS patients without TMD or AL (DS without leu-
kemia) and two AMKL patients without DS were also
analyzed for comparison.
Statistical analysis
Statistical analyses were performed using SPSS statistical
package, version 11.5 (SPSS Inc., Chicago, IL, USA). The
Student t test or Mann-Whitney rank test was used for
direct comparisons between groups. Data are presented as
the mean  standard deviation. OS percentages and stan-
dard errors were calculated using the Kaplan-Meier
method, and log-rank tests were used for group compari-
sons. A p value < 0.05 was considered statistically
significant.(103/mL)
ALT (U/L) 84  90 135  270 0.726
AST (U/L) 89  55 82  85 0.880
LDH (U/L) 3338  1874 2025  2172 0.319
UA (mg/dL) 6.9  5.4 5.5  1.5 0.420
ALT Z alanine transaminase level; AST Z aspartate trans-
aminase level; DS-AL Z Down syndromeeacute leukemia;
F Z female; Hb Z hemoglobin level; LDH Z lactate dehydro-
genase level; M Z male; TMD Z transient myeloproliferative
disorder; UA Z uric acid level; WBC Z white blood cell.
Table 2 Comparison between survivors and nonsurvivors
in DS-AML patients.
Died
(n Z 11)
Survived
(n Z 5)
p
Sex (M/F) 6/5 3/2 0.635
Age (mo) 31.6  16.9 20  8.6 0.174
Relapsed 5 (45%) 0 (0%) 0.013
WBC count (103/mL) 31  53 28  47 0.938
Hb (g/dL) 5.8  2.4 8.8  2.7 0.044
Platelet count (103/mL) 29  26 49  53 0.316
DS-AML Z Down syndromeeacute myeloid leukemia;
F Z female; Hb Z hemoglobin level; M Z male; WBC Z white
blood cell.Results
Clinical presentations and outcomes
The patients’ clinical characteristics are detailed in Table
S2. Most DS patients had TMD (n Z 8), AMKL (n Z 6), or
acute erythromegakaryoblastic leukemia (FAB M6/M7,
mixed lineage; n Z 4; Fig. 1). Compared with DS-AL pa-
tients, DS-TMD patients were younger (0.34  0.46 months
old vs. 29.1  15.7 months old; p < 0.001), had a higher Hb
level (12.7  4.4 g/dL vs. 6.9  2.7 g/dL; p < 0.001) and
higher platelet level (165  223 k/mL vs. 35.9  35.1 k/mL;
p Z 0.026). Other parameters were indistinguishable
(Table 1).
The OS rate in 16 DS-AML patients was 31% and increased
after the year 2008, although not significantly (17% vs 75%;
pZ 0.063). Survivors had a lower relapse rate (0% vs. 45%;
p Z 0.013) and higher Hb level (8.8  2.7 g/dL vs.
5.8  2.4 g/dL; pZ 0.044) than nonsurvivors (Table 2). The
survival outcome was better among those receiving stan-
dard treatment than those receiving incomplete treatment
(median survival 48.5 months vs. 3 months, p Z 0.0013;
Fig. 2). Five patients (31%) relapsed, including three
treated with the AML 97A half-dose protocol, one with the
AML 97B protocol, and one with the DS 2008 protocol. The
median survival time was significantly worse among
relapsed patients than nonrelapsed patients (18.2 months
Figure 2 Ten-year overall survival (OS). Outcome was better
in patients receiving standard treatment (vs. incomplete
treatment; p Z 0.0013).
Figure 3 Ten-year overall survival (OS). Outcome was worse
in relapsed patients (vs. nonrelapsed; p Z 0.0299).
Outcome of Down syndrome with leukemia 97vs. not reached at 120 months; pZ 0.0299; Fig. 3), and age
was significantly older among relapsed patients than non-
relapsed patients (43.8  18 months old vs. 21.6  8.6
months old; p Z 0.025).GATA1 mutation analysis
GATA1 mutation was investigated in 11 patients with DS-
TMD or DS-AL and in DNA extracted from either bone
marrow (in 2 DS-TMD patients and all DS-AL patients) or
peripheral blood (in 1 DS-TMD patient). GATA1 gene muta-
tion was detected in 90% of patients tested (i.e., 3 of 3 DS-
TMD patients and 7 of 8 DS-AL patients). All GATA1 muta-
tions were novel mutations clustering in exon 2 (Table 3).
Eight mutations [7 premature termination codon (PTC) type
1e3 mutations and 1 PTC type 1e5 mutation] resulted in
premature termination of translation and two mutations
resulted in splicing errors. No GATA1 mutation was detec-
ted in DS patients without leukemia (n Z 13) and non-DS
patients with AMKL (n Z 2; Table 4). Of the 10 patients
with GATA1 mutation, six patients (60%) survived with
remission. The one patient who lacked a detectable GATA1
mutation relapsed and died.Discussion
This study analyzed the clinical long-term outcomes of 25
DS patients with hematopoietic disorders. The OS was 40%.
For DS-AML patients, outcome was better in patients who
received standard chemotherapy treatment, had a higher
initial Hb level, and had not relapsed.
The OS rate was quite low and 10 of 17 (58.8%) DS-AL
patients died. However, only one patient died after the
year 2008 (due to relapse). Familial support plays a role in
compliance with chemotherapy. In the period before 2008,
most mortality was due to factors affecting relapse such as
the negative attitudes of family members and consequently
their provision of relatively poor supportive care. After year
2008, the revised treatment protocol and more aggressive
supportive care provided by parents increased the survival
rate. Nevertheless, the 3-year OS rate among Down syn-
drome patients with relapsed acute leukemia remains low
(i.e., only 25.9% in the study by Taga et al28 and 40% in our
study). Taga et al28 identified a long interval between initial
diagnosis and relapse as a significant favorable prognostic
factor. Although we did not identify this factor, possibly
due to the small sample size, we did notice that relapsed
patients were older. We supposed that disease in older DS-
AML patients was of a distinct subtype that was relatively
more resistant to therapy. These patients either failed to
achieve remission or eventually relapsed after treatment.
In previous reports, outcomes were worse and treatment
requirements more dose-intensive in children with DS than
in those without DS.9,19,29 Taga et al28 also noted that
second-line chemotherapy was less likely to achieve com-
plete remission in patients who relapsed earlier.
The GATA1 mutation rate in our study was 90%, which is
similar to previously reported mutation rates of 97.3% in DS-
TMD and around 89.2% in DS with acute megakaryoblastic
leukemia.8 Until now, >100 GATA1 mutations have been re-
ported, mostly occurring in exon 2 and causing protein
truncation.2 Our mutations were also located in exon 2 or
intron 2, suggesting that this region is amutagenesis hotspot.
The Hb level was higher in survivors than nonsurvivors
(8.8  2.7 g/dL vs. 5.8  2.4 g/dL; pZ 0.044), higher in DS-
TMD than in DS-AL patients, and may indicate better overall
health and health benefits, such as lower leukemia burden,
less bleeding tendency, and better oxygen supply. Although
treatment prognosis is multifactorial, a higher Hb level
appeared to be associated with better outcome. Further
studies are needed to confirm this hypothesis.
The major limitation of this study is the relatively small
sample size. It would have been more valuable to conduct a
multicenter, prospective cohort study over the same period
of time. Nonetheless, this study is the first in the literature
to provide a large-scale retrospective clinical and molecu-
lar assessment of DS patients with hematopoietic disorders
in the Chinese population. Also, because the study was
conducted over a long period, we were able to follow
treatment outcome as treatment strategies evolved. Before
the era of the DS-AML specific protocol, physicians in
Taiwan most often used a modified TPOG AML protocol.
However, the outcome of treatment (because of variation
in drug dose and frequency) was less than optimal. The DS
2008 protocol incorporated the half-dose regimen used in
Table 4 GATA1 mutation analysis in TMD, DS-AML, AMKL without DS, and DS without leukemia.
Sample origin TMD (n Z 3) DS-AML (n Z 9) AMKL without DS (n Z 2) DS without leukemia (n Z 13)
Bone marrow 2/2 (100%) 5/6 (83.3%) 0/2 0/0
Peripheral blood 1/1 (100%) 2/3 0/0 0/13
AMKL Z acute megakaryoblastic leukemia; DS Z Down syndrome; AML Z Down syndromeeacute myeloid leukemia; GATA1 Z GATA
binding protein 1; TMD Z transient myeloproliferative disorder.
Table 3 GATA1 mutation analysis.
Patient Diagnosis Location GATA1 mutation Consequence of mutation Mutation type
2 TMD Intron 2 del6bp from IVS2þ1 Splice mutant Splicing error
5 TMD Exon 2 183 ins CC Frameshift at codon 61, stop at codon 198 PTC 1e30
8 TMD > AML M7 Exon 2 194e267 del 74 bp Frameshift at codon 65, stop at codon 408 PTC 1e30
13 AML, M6 Exon 2 139 ins C Frameshift at codon 47, stop at codon 114 PTC 1e30
16 AML, M6/7 Exon 2 87 ins 55 bp Frameshift at codon 29, stop at codon 57 PTC 1e50
17 AML, M6/7 Exon 2 192 ins 22 bp Frameshift at codon 62, stop at codon 207 PTC 1e30
18 AML, M6/7 Exon 2 157 ins GAGCACA Frameshift at codon 53, stop at codon 70 PTC1e30
20 AML, M7 Exon 2 150 del 27 bp ins TACT Frameshift at codon 51, stop at codon 59 PTC 1e30
22 AML, M7 Intron 2 IVS2-1G > C Splice mutant Splicing error
23 AML, M7 d No mutation d d
24 AML, M7 Exon 2 189 ins GCCTACTA Tyr63 stop PTC 1e30
AML Z acute myeloid leukemia; GATA1 Z GATA binding protein 1; PTC Z premature termination codon; TMD Z transient myelopro-
liferative disorder.
98 M.-J. Li et al.the AML 97A protocol but reduced the Ara-C dose by 25%,
added intrathecal MTX to the induction regimen, and
replaced L-asparaginase with mitoxantrone in the consoli-
dation regimen. The TPOG reported that, as a result, the OS
rate improved to 92% (unpublished). Thus, in DS-AL pa-
tients, less intensive chemotherapy and better supportive
care produces the best outcome, thereby giving credence
to the use of this strategy in such patients.
In conclusion, the outcome of DS patients with AML when
treated appropriately is optimal. Supportive care
improvement and treatment protocol modification
increased the OS rate in Taiwan after the year 2008.
Relapse remains a problem for DS-AML patients and a
further larger-scale study is warranted.
Appendix A. Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.jfma.2015.01.009.References
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